Sana Biotechnology, Inc. — Q1 2023 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2023. Sana is a development-stage biotechnology company developing engineered-cell therapies and in vivo cell-engineering technologies. It had no approved products and generated no product revenue. The filing reports that the FDA cleared the SC291 investigational new drug application in January 2023 and that the company began enrolling patients in a Phase 1 trial; initial SC291 data were expected in 2023.
Financial performance, liquidity and obligations
| Metric | Q1 2023 | Q1 2022 / comparator |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $67.2 million | $72.7 million |
| General and administrative expense | $16.8 million | $14.4 million |
| Net loss | $82.1 million; $0.43 per share | $31.4 million; $0.17 per share |
| Cash used in operating activities | $79.3 million | $77.7 million |
| Capital expenditures | $2.2 million | $7.5 million |
- At March 31, cash and cash equivalents were $160.5 million and marketable securities were $194.7 million, totaling $355.1 million. Management said available funds were expected to cover working capital and capital expenditures for at least 12 months.
- Cash, cash equivalents and restricted cash declined $16.3 million in the quarter. Investing activities provided $62.7 million, primarily reflecting maturities of marketable securities, partly offset by purchases and capital expenditures.
- No debt was outstanding. Operating lease liabilities totaled $114.5 million; undiscounted operating lease payments were $242.3 million. Total assets were $746.9 million and stockholders’ equity was $428.3 million.
- Level 3 Cobalt contingent consideration was valued at $155.8 million; Cobalt and Harvard success-payment liabilities totaled $15.7 million. These obligations are subject to remeasurement and may be payable in cash or stock, depending on the agreement.
Material changes versus the prior comparable period
- Net loss increased $50.7 million year over year. A major factor was the difference in remeasurement gains: Q1 2022 included a $55.4 million net gain on success-payment and contingent-consideration valuations, while Q1 2023 recorded a net expense of $0.1 million for those items.
- R&D expense decreased $5.5 million, primarily because Q1 2022 included technology-licensing costs for CD22 and BCMA programs; lower laboratory and third-party manufacturing costs also contributed. Facility and personnel costs increased.
- G&A expense increased $2.3 million, with contributions from costs associated with the previously planned manufacturing facility and higher stock-based compensation and personnel costs.
- Operating cash use was broadly similar to Q1 2022 despite the higher reported net loss, in part because the prior-year period included substantial non-cash valuation gains.
Outlook, commentary and key risks
- Management expected initial SC291 clinical data and data from an investigator-sponsored type 1 diabetes islet-cell trial in 2023. Planned IND timing included SC262 and SG299 in 2023, SC255 in 2024, and SC451 as early as 2024. These are forward-looking plans, not assured outcomes.
- Management expected operating losses and expenses to remain relatively flat over the next few years, with potential increases over the longer term if clinical programs advance. It said program investment would be prioritized and gated against milestones.
- The company had no product revenue, expected continued losses, and anticipated needing additional financing in the future. Its $150 million at-the-market equity facility had generated immaterial net proceeds through March 31, 2023; future equity issuance could dilute shareholders.
- Key risks include unproven cell-engineering platforms; clinical, regulatory and safety uncertainty, including potential genomic changes; manufacturing scale-up and reliance on CDMOs and suppliers; execution and cost risks for the Bothell facility; competition for talent; intellectual-property and licensing dependence; and macroeconomic, supply-chain and financing uncertainty.
- The filing states that Sana intends to sublease or terminate its Fremont manufacturing lease, but gives no assurance that it can do so on acceptable terms. The Bothell lease commenced in Q1 and has a 16-year initial term.
- Fair-value changes in contingent consideration and success payments can materially affect reported expenses and net loss without corresponding operating cash flows. Sana disclosed no material legal proceedings, and management concluded disclosure controls were effective as of quarter-end.
Important facts for investors to verify
- Whether SC291 enrollment and the stated 2023 data timeline progressed as planned, and whether other anticipated IND submissions remain on schedule.
- Whether $355.1 million of cash and marketable securities remains sufficient under actual operating costs, clinical progress and manufacturing commitments.
- How Cobalt contingent-consideration valuations and potential Cobalt and Harvard success payments may change, including possible cash obligations or share dilution.
- Progress and total costs of the Bothell manufacturing build-out, and the status and cost implications of the Fremont lease.
- The filing contains inconsistent language on clinical status: the MD&A says the SC291 Phase 1 trial began enrolling, while later risk-factor boilerplate says no product-candidate clinical trials had commenced. Confirm the current status from subsequent company disclosures.